Late HAART — Competitive Intelligence Brief

Late HAART (Late HAART) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy. Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy Infectious Disease / Virology Small molecule

Target snapshot

Late HAART (Late HAART) — Hospital Nossa Senhora da Conceicao. Late HAART is a combination antiretroviral therapy regimen that suppresses HIV replication by inhibiting multiple stages of the viral life cycle.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Late HAART TARGET	Late HAART	Hospital Nossa Senhora da Conceicao	marketed	Antiretroviral combination therapy
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)
TDF/3TC/EFV	TDF/3TC/EFV	Peking Union Medical College Hospital	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
rilpivirina + emtricitabina + tenofovir	rilpivirina + emtricitabina + tenofovir	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiretroviral combination therapy (NNRTI + 2 NRTIs)	HIV reverse transcriptase
BIC/FTC/TAF	BIC/FTC/TAF	Prism Health North Texas	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Switch to Triumeq	Switch to Triumeq	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy class)

1. ANRS, Emerging Infectious Diseases · 1 drug in this class
2. Chang Gung Memorial Hospital · 1 drug in this class
3. Danish HIV Research Group · 1 drug in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Hospital Nossa Senhora da Conceicao · 1 drug in this class
6. Kristine Patterson, MD · 1 drug in this class
7. PETHEMA Foundation · 1 drug in this class
8. University of Alberta · 1 drug in this class
9. University of North Carolina, Chapel Hill · 1 drug in this class